Chang Pei-Hung, Yeh Kun-Yun, Wang Cheng-Hsu, Chen Eric Yen-Chao, Yang Shih-Wei, Huang Jen-Seng, Chou Wen-Chi, Hsieh Jason Chia-Hsun
Division of Hemato-oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung and Chang Gung University, College of Medicine, Taiwan, Republic of China.
Cancer Center, Chang Gung Memorial Hospital, Keelung, Taiwan, Republic of China.
Head Neck. 2017 Oct;39(10):1990-1996. doi: 10.1002/hed.24853. Epub 2017 Jul 7.
The purpose of this study was to evaluate the impact of the pretreatment Glasgow prognostic score on treatment-related toxicities, tolerance, and survival in patients with advanced head and neck cancers undergoing concurrent chemoradiotherapy (CRT).
We retrospectively analyzed and compared the clinical characteristics, toxicities, and survival of 143 patients with stages III, IVA, and IVB head and neck cancer treated with concurrent CRT according to their Glasgow prognostic score between 2007 and 2010.
The Glasgow prognostic score was correlated with advanced tumor stage and T/N classification. Patients with a higher Glasgow prognostic score were less likely to tolerate concurrent CRT, experienced more weight loss, required tube feeding support more frequently, and had higher percentage of grade ≥3 hematological toxicities, sepsis, and toxic death. Patients with a Glasgow prognostic score of 0 had better overall and recurrence-free survival than those with a Glasgow prognostic score of 1 or 2.
Pretreatment Glasgow prognostic score predicts treatment tolerance, toxicity, and survival in patients with advanced head and neck cancer undergoing concurrent CRT.
本研究旨在评估治疗前格拉斯哥预后评分对接受同步放化疗（CRT）的晚期头颈癌患者治疗相关毒性、耐受性和生存率的影响。
我们回顾性分析并比较了2007年至2010年间根据格拉斯哥预后评分接受同步CRT治疗的143例III期、IVA期和IVB期头颈癌患者的临床特征、毒性和生存率。
格拉斯哥预后评分与肿瘤晚期阶段和T/N分类相关。格拉斯哥预后评分较高的患者更难耐受同步CRT，体重减轻更多，更频繁地需要管饲支持，且≥3级血液学毒性、脓毒症和毒性死亡的发生率更高。格拉斯哥预后评分为0的患者的总生存率和无复发生存率优于评分为1或2的患者。
治疗前格拉斯哥预后评分可预测接受同步CRT的晚期头颈癌患者的治疗耐受性、毒性和生存率。
